The CER Groupe offers a fully integrated solution based on an innovative state-of-the-art technologies and services portfolio, including in-vivo/in-vitro pre-clinical facilities supported by specialized analytical platforms.
Our team of scientific and technical experts strives to deliver reliable results, from feasibility studies to assay development and validation, and for routine testing . Our goal is to meet your requirements by offering flexible and bespoke solutions that are integrated into relevant quality-management systems, from discovery to GLP studies.
CER Groupe is also very active in the field of pre-toxicology studies in order to support companies with their risk-management strategy.
Indeed, CER Groupe offers solutions for investigating reliable and predictive human models in vitro, thus complementing the relevance of the data generated during pre-clinical phases on in-vivo animal models.
The team has extensive experience in immunology, oncology and diabetes, osteoarticular, and medical devices, and offers custom development services for specific applications.
Our team of scientific and technical experts strives to deliver reliable results, from feasibility studies to assay development and validation, and for routine testing.
Our analytical platform includes:
- non-invasive in-vivo imaging
- flow cytometry
- ELISA work stations (mixed-mode)
- MSD technology for multiplex electrochemiluminescence immuno-assays
- real-time in-vitro cell imaging
- in-vitro gene reporting
- mass spectrometry, including HRMS (small molecules/metabolomic and proteomic)
- Determination of molecular interaction (Octet ForteBio)
11 complementary analytical platforms
minimum of 1 expert dedicated to each platform
> 2,500 Samples analyzed in 2021